An interventional study of Reactivate in Chronic Pain and Emotional Distress, sponsored by Örebro University, Sweden. Active, not recruiting at 1 site in Sweden. Open to participants aged 12 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Örebro University, Sweden · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Chronic Pain with a site in Sweden — 30 open to participants now, 37 under way, none of them phase 3. Chronic Pain · Sweden.
Among the 88 studies in Chronic Pain with a site in Sweden, this one is the 47th largest by planned enrollment of the 65 interventional ones that give a count, is one of 7 that started in 2024, is one of 61 with no phase, reaches primary completion later than 12 of the 36 other live ones, and was the 68th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →30 of the 88 studies in Chronic Pain with a site in Sweden are open now. Recruiting first, the newest first:
Skane University Hospital · Sites in Sweden
Ages 15–24
Karolinska Institutet · Sites in Sweden
Ages 18+
Skane University Hospital · Sites in Sweden
Ages 18–65
Catholic University of the Sacred Heart · Sites in Sweden, Italy
Ages 18+
Lund University · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 12 Years to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 1 · Phase 4 1
First in 2004; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is below the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 80 across the 65 interventional studies, 144 across the 23 observational. Of the 44 that completed or were terminated, 3 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 88 have an industry lead sponsor. The 10 most frequent:
Örebro University, Sweden is the lead sponsor of 87 studies on the registry; 15 are open to participants now.
Örebro University, Sweden has 4 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
11 of the studies in Chronic Pain with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06410963Örebro University, SwedenReActivate: Physiotherapist Led Intervention for A Adolescents and Young Adults With Musculoskelatal Pain | 2026-11-30 |
| NCT06981312Region StockholmInternet-Delivered Psychological Treatments for Chronic Pain in Adolescents: ACT and Pain Education. | 2026-12 |
| NCT06084390Vastra Gotaland RegionInterdisciplinary Rehabilitation for Chronic Pain in Primary Healthcare | 2026-12-31 |
| NCT06981611Karlstad UniversityVulvodynia Intervention: the Effect of Multimodal Treatment for Provoked Vulvodynia | 2026-12-31 |
| NCT07092332Region Örebro CountyYoung Vulvodynia: Effect and Efficacy of Multimodal Treatment. | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 88 studies in Chronic Pain with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Recurrent or persistent musculoskeletal pain is an alarmingly common problem among adolescents, in Sweden as well as globally. Pain often co-occur with and psychological distress and have both been shown to be predictors of sustained problems in adulthood. Adequate treatment early on in the development of problems has been shown important in order to decrease the risk of sustained problems in adulthood but available treatments have only modest effects. There is thus a need for treatment development, not in the least for (secondary) preventative purposes. The aim of this project is therefore to develop an evidence based and cost-effective secondary preventative intervention. Specifically, this project aims to develop and test a physiotherapist led treatment for adolescents with recurrent or persistent musculoskeletal pain and based upon graded exposure to physical activity and reactivation.
See description of arms and intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants are randomized to a 7, 14 or 21 day waiting period. Daily measurements are collected throughout this period.
Reactivate treatment. Daily measurements are collected throughout treatment.
Behavioral: Reactivate
The study period is 84 days (12 weeks). Depending on the length of the baseline period (randomly assigned to be 7, 14 or 21 days), the treatment period varies between 63-77 days and contains 6-11 sessions. The intervention consists of 2-4 educational sessions in pain mechanisms and fear avoidance and 4-9 sessions of individually tailored intervention with graded exposure and reactivation to avoided physical activities. Intervention will take place from one time per week to one time every two weeks, 30-60 minutes per session. Number of treatment sessions will depend on when the individual participants' goals are considered reached. If necessary, given the participants consent, their legal guardians will be invited to attend the sessions.
Activity engagement change
Change in self-rated activity engagement. Numerical Rating Scale, range 0-6 (1 question: lower values, worse outcome, 1 question: Lower values, better outcome )
Time frame: repeated daily through phase A (randomly assigned to be 7, 14 or 21 days) and treatment phase B (9-11 weeks). Total time frame of assessment is 12 weeks (84 days). 7 days assessment 6 months after terminated intervention
Symptom distress change
Change in self-rated distress about symptoms. Numerical Rating Scale, range 0-6 (3 questions, higher values, worse outcome)
Time frame: repeated daily through phase A (randomly assigned to be 7, 14 or 21 days) and treatment phase B (9-11 weeks). Total time frame of assessment is 12 weeks (84 days). 7 days assessment 6 months after terminated intervention.
Functional Disability Inventory (FDI) change
Change in functional disability. Descriptive Rating Scale, range 0-64 (higher values, worse outcome)
Time frame: baseline, after treatment phase B (12 weeks), 6 months after terminated intervention
Center of Epidemiological Studies Depression Scales for Children (CES-DC) change
Change in depressive symptoms. Descriptive Rating Scale, range 0-60 (higher values, worse outcome)
Time frame: baseline, after treatment phase B (12 weeks), 6 months after terminated intervention
The Pediatric Quality of Life Acute version (PedsQL) PedsQL™
Change in quality of life. Descriptive Rating Scale, range 0-92 (higher values, worse outcome)
Time frame: baseline, after treatment phase B (12 weeks), 6 months after terminated intervention
Change in psychological distress
Change in self-related symptoms of psychological distress. Numerical Rating Scale, range 0-6 (3 questions, higher values, worse outcome)
Time frame: repeated daily through phase A (randomly assigned to be 7, 14 or 21 days) and treatment phase B (9-11 weeks). Total time frame of assessment is 12 weeks (84days). 7 days assessment 6 months after terminated assessment.
Pain change
Change in self-related pain symptoms. Numerical Rating Scale range 0-6 (higher values, worse outcome)
Time frame: repeated daily through phase A (randomly assigned to be 7, 14 or 21 days) and treatment phase B (9-11 weeks). Total time frame of assessment is 12 weeks (84days). 7 days assessment 6 months after terminated assessment.
Fear of Pain Questionnaire Children Short-form (FOPQ-C SF) change
Change in fear of pain. Descriptiv Rating Scale, range 0-40 (higher values worse outcome)
Time frame: baseline, after treatment phase B (12 weeks), 6 months after terminated intervention
The Photograph Series of Daily Activities for youth (PHODA) change - short
Change in percieved harmfulness. Photographs with 50 activities, rated on a Subjective Self-rating Scale, range 0-100mm/item (higher values, worse outcome)
Time frame: First session after baseline (randomly assigned to be 7, 14 or 21 days), after treatment phase B (12 weeks)
Treatment Inventory of Costs in Patients with psychiatric disorders (Tic-P), medical resources
Change in use of medical resources. Dichotomous scale completed by open ended answers if answer is yes.
Time frame: baseline, 12 weeks, 6 months after terminated intervention
Treatment Inventory of Costs in Patients with psychiatric disorders (Tic-P), school absence
Change in school abcense. Dichotomous scale completed by open ended answers if answer is yes. One question is completed by one question with Numerical Rating Scale 1-10 (higher values, worse outcome) if answer is yes.
Time frame: baseline, 12 weeks, 6 months after terminated intervention
Accelerometer
Change in physical activity, digital device counting steps
Time frame: 7 days of the first week of baseline (randomly assigned to be 7, 14 or 21 days). 7 days assessment 6 months after terminated assessment.
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Nov 2026, 26 months after the start.
Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 26 months is above that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Örebro University, Sweden